This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Zuellig Pharma Acquires Zam-Buk, Vapex Brands
Business Acquisition

Zuellig Pharma Acquires Zam-Buk, Vapex Brands

Analysis based on 7 articles · First reported Feb 09, 2026 · Last updated Feb 09, 2026

Sentiment
30
Attention
2
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The acquisition by Zuellig Pharma is expected to strengthen its position in the Asian consumer healthcare market, potentially increasing competition for other players. For Bayer, it represents a strategic divestment of non-core assets in the region.

Pharmaceuticals Consumer goods
Event Summary

Zuellig Pharma, a prominent healthcare solutions company in Asia, announced on February 9, 2026, the acquisition of all rights, title, and interest in the Zam-Buk and Vapex consumer healthcare brands from Bayer Consumer Care AG. This acquisition covers the markets of Thailand, Singapore, Indonesia, Malaysia, and Brunei. Zam-Buk, launched in 1902, is an ointment for pain and itch relief, while Vapex, launched in 1917, is a nasal inhaler. This move aligns with Zuellig Pharma's strategy to expand its consumer healthcare portfolio across Asia and marks its second such acquisition, following Propan in the Philippines. John Graham, CEO of Zuellig Pharma, emphasized that this acquisition is a significant growth milestone, aiming to leverage Zuellig Pharma's regional commercial capabilities and local market expertise to expand distribution and access for these trusted brands.

Key Actions
95 Zuellig Pharma acquired rights to consumer healthcare brands Bayer
90 Bayer sold rights to consumer healthcare brands Zuellig Pharma
Entities Involved
priv
Zuellig Pharma
Zuellig Pharma acquired the rights to the Zam-Buk and Vapex consumer healthcare brands, strengthening its consumer healthcare portfolio and expanding its presence in Asia. This acquisition is a significant growth milestone for the company.
Importance 90 Sentiment 40
stock
Bayer
Bayer Consumer Care AG sold the rights to its Zam-Buk and Vapex brands in several Southeast Asian countries to Zuellig Pharma. This move allows Bayer to divest certain consumer healthcare assets in the region.
Importance 70 Sentiment 10
per
John Graham
John Graham, CEO of Zuellig Pharma, commented on the acquisition, highlighting its importance for the company's consumer healthcare portfolio and regional expansion.
Importance 50 Sentiment 0
cnt
Thailand
Thailand is one of the key markets where Zuellig Pharma acquired the rights to the Zam-Buk and Vapex brands, with Vapex having built meaningful brand recognition particularly in Thailand.
Importance 20 Sentiment 0
cnt
Singapore
Singapore is one of the markets where Zuellig Pharma acquired the rights to the Zam-Buk and Vapex brands.
Importance 20 Sentiment 0
cnt
Indonesia
Indonesia is one of the markets where Zuellig Pharma acquired the rights to the Zam-Buk and Vapex brands.
Importance 20 Sentiment 0
cnt
Malaysia
Malaysia is one of the markets where Zuellig Pharma acquired the rights to the Zam-Buk and Vapex brands.
Importance 20 Sentiment 0
+ 1 more entities View on Dashboard
Relationships
John Graham related ↔ Zuellig Pharma
Zuellig Pharma related ↔ Bayer
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.